Akero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ...

GuruFocus.com05-13

Net Loss: Reported a net loss of $53.34 million for the first quarter of 2024, which was less than the estimated net loss of $54.55 million. EPS: Reported an EPS of -$0.90, surpassing the estimated ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2435248367?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/3JF95zCf1EWFbT42yIyfTw--~B/aD01NTc7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/13092b68b7e889aaf3049efb172a71a4","is_english":true,"pubTime":"2024-05-13 09:01","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2435248367","market":"us","top_or_hot":-1,"title":"Akero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ...","media":"GuruFocus.com","content":"<div>\n<p>Net Loss: Reported a net loss of $53.34 million for the first quarter of 2024, which was less than the estimated net loss of $54.55 million.\nEPS: Reported an EPS of -$0.90, surpassing the estimated ...</p>\n\n<a href=\"https://finance.yahoo.com/news/akero-therapeutics-inc-akro-q1-010149084.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-13 09:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/akero-therapeutics-inc-akro-q1-010149084.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Net Loss: Reported a net loss of $53.34 million for the first quarter of 2024, which was less than the estimated net loss of $54.55 million.\nEPS: Reported an EPS of -$0.90, surpassing the estimated ...</p>\n\n<a href=\"https://finance.yahoo.com/news/akero-therapeutics-inc-akro-q1-010149084.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AKRO","symbol_name":"Akero Therapeutics","start_time":0,"source_url":"https://finance.yahoo.com/news/akero-therapeutics-inc-akro-q1-010149084.html","article_id":"2435248367","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/3JF95zCf1EWFbT42yIyfTw--~B/aD01NTc7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/13092b68b7e889aaf3049efb172a71a4"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2435248367","pubTimestamp":1715562109,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Net Loss: Reported a net loss of $53.34 million for the first quarter of 2024, which was less than the estimated net loss of $54.55 million.EPS: Reported an EPS of -$0.90, surpassing the estimated EPS of -$0.95.Revenue: Reported revenue met the estimate of $0.00 million.Research and Development Expenses: Increased significantly to $50.65 million, up from $21.79 million in the same quarter the previous year.Total Assets: Increased to $912.24 million as of March 31, 2024, up from $580.27 million at the end of 2023.Cash Position: Strengthened with cash, cash equivalents, and short-term marketable securities totaling $903.67 million, a substantial increase from $550.01 million at the end of 2023.Akero Therapeutics Inc  released its 8-K filing on May 10, 2024, detailing its financial results for the first quarter of 2024. The clinical-stage biotechnology company, focused on developing treatments for serious metabolic diseases such as nonalcoholic steatohepatitis , reported a net loss of $53","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"AKRO":"Akero Therapeutics"},"translate_title":"阿克罗治疗公司（AKRO）Q1 2024年收益：低于分析师预测...","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKRO":1},"content_text":"Net Loss: Reported a net loss of $53.34 million for the first quarter of 2024, which was less than the estimated net loss of $54.55 million.\nEPS: Reported an EPS of -$0.90, surpassing the estimated EPS of -$0.95.\nRevenue: Reported revenue met the estimate of $0.00 million.\nResearch and Development Expenses: Increased significantly to $50.65 million, up from $21.79 million in the same quarter the previous year.\nTotal Assets: Increased to $912.24 million as of March 31, 2024, up from $580.27 million at the end of 2023.\nCash Position: Strengthened with cash, cash equivalents, and short-term marketable securities totaling $903.67 million, a substantial increase from $550.01 million at the end of 2023.\nStockholders' Equity: Grew to $846.25 million, up from $535.31 million at the end of the previous year.\n\n\nWarning! GuruFocus has detected 3 Warning Signs with AKRO.\n\n\nAkero Therapeutics Inc (NASDAQ:AKRO) released its 8-K filing on May 10, 2024, detailing its financial results for the first quarter of 2024. The clinical-stage biotechnology company, focused on developing treatments for serious metabolic diseases such as nonalcoholic steatohepatitis (NASH), reported a net loss of $53.34 million for the quarter, which translates to a loss of $0.90 per share. This result misses the analyst estimates that projected a loss of $0.95 per share.\nCompany Overview and Clinical Developments\nAkero Therapeutics is at the forefront of addressing NASH, a critical area with high unmet medical needs and no approved therapies. Their lead candidate, efruxifermin (EFX), is designed to tackle the core processes underlying NASH pathogenesis. During the first quarter, significant progress was made in the clinical development of EFX, particularly with the Phase 2b HARMONY study showing promising results over a 96-week period.\nFinancial Highlights and Strategic Funding\nThe company's financial health is supported by a robust balance sheet, boasting $903.7 million in cash, cash equivalents, and short-term marketable securities following a successful equity offering in March 2024. This positions Akero well to fund its operations and ongoing clinical trials into the second half of 2027. Total assets have significantly increased to $912.2 million from $580.3 million at the end of the previous year.\nDetailed Financial Analysis\nDespite the promising clinical advancements, Akero's operating expenses have more than doubled compared to the same period last year, primarily due to increased investments in research and development which surged to $50.65 million from $21.79 million. This substantial increase underscores the company's commitment to advancing its clinical programs, particularly the Phase 3 SYNCHRONY studies and the ongoing Phase 2b trials.\nMarket and Future Outlook\nThe potential market for NASH treatments is significant, with an estimated 17 million Americans affected by the disease, which is a leading cause of liver transplants in the US and Europe. Akero's strategic focus on this area, backed by a strong cash position, provides a favorable long-term outlook despite short-term financial losses attributed to heavy R&D expenditures.\nAs Akero Therapeutics continues to navigate the complexities of NASH treatment development, its financial strategy and clinical progress will be critical in shaping the company's trajectory in the highly competitive biotechnology industry.\nConclusion\nWhile the first quarter of 2024 has seen Akero Therapeutics widen its financial losses, the strategic developments in its clinical programs and the strengthened financial position through successful fundraising efforts highlight a clear path forward. The company remains a key player to watch in the biotechnology sector, particularly for investors interested in groundbreaking treatments for metabolic diseases.\nFor detailed financial figures and more information on Akero's operational strategies, visit the full 8-K filing.\n Explore the complete 8-K earnings release (here) from Akero Therapeutics Inc for further details. This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2435248367"}